Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
Masatoshi Kudo(Kindai University), Kiwamu Okita, Toshio Ohya(Bayer (Japan)), Takeshi Hori(University of Toyama), Osamu Matsui(Kanazawa University), Hirohito Tsubouchi(Kagoshima University), Jung‐Hwan Yoon(Seoul National University), Kohei Nakachi(National Cancer Center Hospital East), Junji Furuse(Kyorin University), Iku Yamaguchi(Bayer (Japan)), Won Young Tak(Kyungpook National University Hospital), Takuji Okusaka(National Cancer Center), Michihiko Wada(Bayer (Japan)), Katsuaki Tanaka(Yokohama City University Medical Center), Tadatoshi Takayama(Nihon University), Dong Jin Suh(Asan Medical Center), Hiromitsu Kumada(Toranomon Hospital), Nobuyuki Chida(Sendai Medical Center), Gerold Meinhardt, Kazuho Imanaka(Osaka International Cancer Institute), Shuichi Kaneko(Kanazawa University), Norio Hayashi(Osaka University)
Cited by 573
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k